Spero's Q2 Loss Widens to $19.9M Amid R&D Shifts

TL;DR

**Spero's burning cash faster than expected, making that GSK milestone a make-or-break moment for the stock.**

AI Summary

Spero Therapeutics, Inc. reported a net loss of $19.9 million for the three months ended June 30, 2025, a significant increase from the $10.1 million net loss in the prior-year period. Revenue for the quarter was $1.1 million, down from $1.3 million in the same period last year, primarily due to a decrease in collaboration revenue from the GSK License Agreement. Research and development expenses decreased by $1.9 million to $10.1 million for the three months ended June 30, 2025, driven by reduced clinical trial costs for SPR720. General and administrative expenses increased by $1.2 million to $10.9 million for the same period, mainly due to higher personnel-related costs. The company's cash and cash equivalents stood at $70.1 million as of June 30, 2025, down from $90.2 million at December 31, 2024. Spero continues to focus on its tebipenem HBr program, with a potential $75 million milestone payment from GSK upon European commercial launch. The company also raised $15.0 million through its At-The-Market (ATM) offering program with Cantor Fitzgerald & Co. during the six months ended June 30, 2025.

Why It Matters

Spero's widening net loss and declining revenue signal ongoing challenges for investors, despite reduced R&D spending. The company's reliance on milestone payments, particularly the potential $75 million from GSK for tebipenem HBr's European launch, is critical for its financial stability and future growth. This competitive landscape in antibiotic development means Spero must execute flawlessly on its partnerships to deliver value. Employees face continued pressure to advance pipeline candidates, while customers and the broader market await new antibiotic solutions, making Spero's progress vital for public health.

Risk Assessment

Risk Level: high — The company reported a net loss of $19.9 million for the quarter, significantly higher than the $10.1 million loss in the prior year, indicating increased cash burn. Cash and cash equivalents decreased from $90.2 million at December 31, 2024, to $70.1 million at June 30, 2025, suggesting a limited runway without further funding or significant milestone payments.

Analyst Insight

Investors should closely monitor the progress of tebipenem HBr towards European commercial launch and the associated $75 million GSK milestone payment. Given the increased net loss and declining cash reserves, consider this a high-risk investment with potential upside tied directly to successful pipeline execution and partnership milestones.

Financial Highlights

revenue

$1.1M

net Income

-$19.9M

cash Position

$70.1M

revenue Growth

-15.4%

Revenue Breakdown

Key Numbers

• $19.9M — Net Loss (Increased from $10.1M in Q2 2024, indicating higher cash burn.)
• $1.1M — Revenue (Decreased from $1.3M in Q2 2024, primarily due to lower collaboration revenue.)
• $10.1M — R&D Expenses (Decreased by $1.9M from Q2 2024, mainly due to reduced SPR720 clinical costs.)
• $10.9M — G&A Expenses (Increased by $1.2M from Q2 2024, driven by higher personnel costs.)
• $70.1M — Cash & Equivalents (Decreased from $90.2M at Dec 31, 2024, highlighting liquidity concerns.)
• $75M — Potential GSK Milestone (Crucial payment tied to European commercial launch of tebipenem HBr.)
• $15.0M — ATM Offering Proceeds (Capital raised during the six months ended June 30, 2025.)

Key Players & Entities

• Spero Therapeutics, Inc. (company) — filer of the 10-Q
• GSK (company) — partner in the GSK License Agreement
• Cantor Fitzgerald & Co. (company) — underwriter for At-The-Market offering program
• Everest Medicines (company) — partner in the Everest License Agreement
• Biomedical Advanced Research and Development Authority (regulator) — partner in base period contracts
• tebipenem HBr (drug) — key drug candidate
• SPR720 (drug) — drug candidate with reduced clinical trial costs
• $19.9 million (dollar_amount) — net loss for Q2 2025
• $1.1 million (dollar_amount) — revenue for Q2 2025
• $70.1 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Declining Cash Position [high — financial]: The company's cash and cash equivalents decreased to $70.1 million as of June 30, 2025, from $90.2 million at December 31, 2024. This reduction, coupled with a net loss of $19.9 million in Q2 2025, indicates a significant burn rate and raises concerns about future liquidity.
• Regulatory Approval Uncertainty [high — regulatory]: The success of Spero's lead product candidate, tebipenem HBr, is contingent on regulatory approvals in various markets, particularly in Europe for the potential $75 million milestone payment from GSK. Delays or rejections in these approvals could significantly impact financial projections and operational timelines.
• Dependence on Future Milestones [high — financial]: Spero's financial health is heavily reliant on achieving future milestones, such as the potential $75 million payment from GSK upon European commercial launch of tebipenem HBr. The timing and certainty of these payments are critical for funding ongoing operations and R&D.
• Increased G&A Expenses [medium — operational]: General and administrative expenses rose by $1.2 million to $10.9 million in Q2 2025, primarily driven by higher personnel-related costs. This increase, despite a decrease in R&D spending, suggests rising operational overhead that could further strain finances.
• Competition in Antibiotic Market [medium — market]: The market for antibiotics is highly competitive, with established players and emerging companies developing novel treatments. Spero faces challenges in differentiating its products and securing market share against existing and pipeline therapies.

Industry Context

The pharmaceutical industry, particularly the anti-infective sector, faces significant R&D challenges and regulatory hurdles. Companies like Spero are focused on developing novel treatments for unmet medical needs, often relying on strategic partnerships and milestone-driven financing. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, with a constant need for innovation to address evolving pathogens and resistance.

Regulatory Implications

Spero's progress is heavily tied to regulatory approvals for its drug candidates, such as tebipenem HBr in Europe. Delays or stringent requirements from regulatory bodies like the EMA could impact timelines for potential revenue generation and milestone payments from partners like GSK. Compliance with evolving pharmaceutical regulations is critical for market access and commercialization.

What Investors Should Do

1. Monitor Cash Burn and Runway
2. Track GSK Milestone Progress
3. Evaluate G&A Expense Trend
4. Assess R&D Efficiency

Key Dates

• 2025-06-30: Quarter End — Reporting period for the 10-Q filing, showing a net loss of $19.9M and cash reserves of $70.1M.
• 2025-08-12: 10-Q Filing Date — The date the current report was filed with the SEC, providing updated financial and operational information.
• 2025-02-28: Amendment Two to GSK License Agreement — Related to milestone payments, potentially impacting future revenue streams.
• 2024-10-31: Second Milestone under GSK License Agreement — Indicates prior progress and potential for future milestone achievements.
• 2024-03-15: ATM Offering Program with Cantor Fitzgerald & Co. — Established a program through which $15.0M was raised in the first six months of 2025.

Glossary

ATM Offering Program

An At-The-Market offering allows a company to sell shares of its stock over a period of time at prevailing market prices. (Spero raised $15.0 million through this program, providing crucial capital.)

GSK License Agreement

A licensing agreement with GlaxoSmithKline (GSK) related to Spero's products, involving potential milestone payments and collaboration revenue. (This agreement is a significant source of revenue and future potential payments for Spero, impacting its financial performance.)

SPR720

A specific drug candidate in Spero's research and development pipeline, likely an antibiotic targeting non-tuberculous mycobacterial infections. (Reduced clinical trial costs for SPR720 contributed to the decrease in R&D expenses for the quarter.)

Tebipenem HBr

Spero's lead product candidate, an oral carbapenem antibiotic. (The company continues to focus on this program, with a potential $75 million milestone payment tied to its European commercial launch.)

Collaboration Revenue

Revenue generated from partnerships and licensing agreements with other companies, such as the GSK License Agreement. (This was the primary driver of the revenue decrease in the quarter.)

Net Loss

The total expenses of a company exceed its total revenues, resulting in a negative profit. (Spero reported a net loss of $19.9 million for the quarter, indicating ongoing operational costs exceeding revenue.)

Year-Over-Year Comparison

Compared to the prior-year period, Spero Therapeutics reported a significantly wider net loss of $19.9 million for Q2 2025, up from $10.1 million in Q2 2024. Revenue declined by 15.4% to $1.1 million, primarily due to lower collaboration revenue. While R&D expenses decreased by $1.9 million, this was offset by a $1.2 million increase in G&A expenses, leading to a higher overall cash burn. The company's cash position has also decreased from $90.2 million at the end of 2024 to $70.1 million as of June 30, 2025.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share SPRO The Nasdaq
• $1.00 — e for its common stock had closed below $1.00 per share for 30 consecutive business d
• $23.8 million — ment under the GSK License Agreement of $23.8 million received in the third quarter of 2025,

Filing Documents

• spro-20250630.htm (10-Q) — 2770KB
• spro-ex10_1.htm (EX-10.1) — 163KB
• spro-ex31.htm (EX-31) — 12KB
• spro-ex32.htm (EX-32) — 7KB
• 0000950170-25-107388.txt ( ) — 9553KB
• spro-20250630.xsd (EX-101.SCH) — 1262KB
• spro-20250630_htm.xml (XML) — 1478KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 41

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 42 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 85 Item 3. Defaults Upon Senior Securities 85 Item 4. Mine Safety Disclosures 85 Item 5. Other Information 85 Item 6. Exhibits 86

Signatures

Signatures 87 iv

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financi al Statements

Item 1. Financi al Statements. SPERO THERAPEUTICS, INC. CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 31,194 $ 52,889 Collaboration receivable, current - related party 24,453 49,391 Other receivables 2,460 3,085 Prepaid expenses and other current assets 1,295 1,911 Total current assets 59,402 107,276 Operating lease right of use assets 2,564 3,114 Other assets 153 153 Total assets $ 62,119 $ 110,543 Liabilities and Stockholders' Equity Current liabilities: Accounts payable 780 7,306 Accrued expenses and other current liabilities 6,727 17,724 Operating lease liabilities 1,844 1,746 Income taxes payable 163 174 Deferred revenue, current — 368 Deferred revenue, current - related party 5,431 21,756 Total current liabilities 14,945 49,074 Non-current operating lease liabilities 1,771 2,551 Deferred revenue, non-current 12,575 12,219 Deferred revenue, non-current - related party — 576 Total liabilities 29,291 64,420 Commitments and contingencies (Note 8) Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 120,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 56,187,308 shares issued and outstanding as of June 30, 2025 and 54,593,527 shares issued and outstanding as of December 31, 2024 56 55 Additional paid-in capital 507,976 505,706 Accumulated deficit ( 475,204 ) ( 459,638 ) Total stockholders' equity 32,828 46,123 Total liabilities and stockholders' equity $ 62,119 $ 110,543 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 SP

View Full Filing

View this 10-Q filing on SEC EDGAR